Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 183-187

  Perez Simon J A ^a   Garcia Escobar I ^a   Martinez, J ^a   Vazquez, L ^a   Caballero, D ^a   Canizo C ^a   Mateos, M V ^a   San Miguel, J F ^a  

^a Hospital Provincial de Salamanca   (Spain)

Author keywords

Allogeneic transplant; Antibiotic prophylaxis; Meropenem

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FOLINIC ACID; ITRACONAZOLE; MEROPENEM; METHOTREXATE; TEICOPLANIN; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; BLOOD TOXICITY; CELL COUNT; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRANULOCYTE; HUMAN; INTERMETHOD COMPARISON; LIVER TOXICITY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; VOMITING; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; BACTERIAL INFECTIONS; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PILOT PROJECTS; THIENAMYCINS;

EID: 0842323952     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704335     Document Type: Article

References (34)

1. Feroze Momin MD, Pranatharthi H, Chandrasekar, MD. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 123: 205-215.
2. van der Meer JW, Guiot HF, van der Broek PJ, van Furth R. Infections in bone marrow transplant recipients. Semin Hematol 1984; 21: 123-140.
3. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth supresion of intestinal anaerobic bacteria reduces the risk of acute graft versus host disease after sibling marrow transplantation. Blood 1992; 80: 2668-2676.
4. Pizzo PA. Considerations for the prevention of the infectious complications in immunosuppressed patients with cancer. Rev Infect Dis 1989; 11: 1551-1563.
5. Metcalf D. The colony stimulating factors: discovery, development, and clinical applications. Cancer 1990; 65: 1286-1295.
6. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-1778.
7. Advani R, Chao NJ, Horning SJ et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116: 183-189.
8. Powles R, Smith C, Milan S et al. Human recombinant GMCSF in allogeneic bone marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417-1420.
9. Eric AE, Joseph L, Michael B. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
10. Lew MA, Kehoe K, Ritz J et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630-636.
11. Maiche AG, Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer 1993; 29: 1403-1405.
12. Karp JE, Merz WG, Hendricksen C et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106: 1-7.
13. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med 1988; 84: 847-854.
14. Cruciani M, Concia E, Navarra A et al. Prophylactic cotrimoxazole versus norfloxacin in neutropenic children perspective ramdomized study. Infection 1989; 17: 65-69.
15. Lew MA, Kehoe K, Ritz J et al. Ciprofloxacin versus trimethopim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239-250.
16. Yeh SP, Hsueh EJ, Yu MS, Wang YC. Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal. Bone Marrow Transplant 1999; 24: 1207-1211.
17. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240-1241.
18. Carratalá J, Fernández-Sevilla A, Tubau F et al. Emergence of quinolone resistant Escherichia coli bacteriemia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-560.
19. Kotilainen P, Nikoskelainen J, Huovinen P. Emergence if ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990; 16: 41-44.
20. Kern WV, Markus A, Andriof E. Bacteriemia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994; 13: 161-165.
21. Kern WV, Andriof E, Oethinger M et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681-687.
22. Alarcón T, Pita J, López-Brea M, Piddock LJ. High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J Antimicrob Chemother 1993; 32: 605-609.
23. Ena J, López-Perezagua MM, Martinez-Peinado C et al. Emergence of ciprofloxacin resistanse in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998; 30: 103-107.
24. Schmeisser T, Kurrle E, Arnold R et al. Norfloxacin for the prevention of bacterial infection during severe granulocytopenia after bone marrow transplantation. Scand J Infect Dis 1988; 20: 625-631.
25. Menichetti F, Felicini R, Bucaneve G et al. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant 1989; 4: 489-492.
26. Lew MA, Kehoe K, Ritz J et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630-636.
27. Krochinsky F, Wichmann G, Bornhauser M et al. Efficacy and tolerability of prophylaxic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. Transplant Infect Dis 2002; 4: 132-136.
28. Classen DC, Burke JP, Ford CD et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990; 89: 441-446.
29. Oppenheim BA, Hartley JW, Lee W, Burnie JP. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukemia unit. BMJ 1989; 299: 294-297.
30. Broun ER, Wheat JL, Kneebone PH et al. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 1994; 38: 576-579.
31. Kern WV, Hay B, Kern P et al. A randomized trial of reoxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother 1994; 38: 465-472.
32. Guiot HFL, Corel LJA, Bossen JMHJ. Prevalence of penicillin-resistant viridians streptococci in healthy children and in patients with malignant haematological disorders. Eur J Clin Microbiol Infect Dis 1994; 13: 645-650.
33. Orlandi E, Navarra A, Cruciani M et al. Norfloxacin versus cotrimoxazole for infection prophylaxis in granulocytopenic patients with acute leukemia. A prospective randomized study. Haematologica 1990; 75: 296-298.
34. Shales DM, Gerding DN, John JF et al. Society for healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-599.